Release Date: Jul 2018
CC: PC, MK, PBL, ICS, PR, SBP
Miguel A. Escobar, MD
Director of Hemophilia and Thrombophilia Center, Houston, TX; Professor of Medicine and Pediatrics, University of Texas Health Science Center and McGovern Medical School, Houston, TX
Acquired hemophilia is a rare bleeding disorder that usually presents in the elderly with high morbidity and mortality. Fifty percent of the cases can be related to malignancy, autoimmune disorders, pregnancy, and infections. The rest are considered idiopathic. Clinical presentation is characteristic for soft tissue hemorrhages and muscle bleeds. However, joint bleeds may also occur as with congenital hemophilia. Diagnosis can be a challenge due to the rarity of occurrence and lack of awareness in the community. Dual therapy is imperative: treatment of acute bleeds with bypassing agents or porcine F8, and immunosuppression to eradicate the antibody. Due to the complexity of their diagnosis and management, these patients should be managed in a hemophilia treatment center.
After attending this session, participants will be able to:
- Explain the epidemiology and multiple conditions associated with acquired hemophilia.
- Describe the clinical presentation and diagnosis of acquired hemophilia, including differential diagnosis.
- Implement the treatment of acute bleeds and therapeutic options for eradication of the antibody.
Who should attend? Practicing Pathologists, Residents, Doctoral Scientists, Pathologists’ Assistants, Laboratory Managers, Bench Supervisors, Bench Technologists and Technicians, Students